Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies

Next Previous
Search
Trial Profile

Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SNS 01 (Primary)
  • Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma; Plasma cell leukaemia
  • Focus Adverse reactions
  • Sponsors Eloxx Pharmaceuticals; Sevion Therapeutics

    • Most Recent Events

    • 22 Dec 2017 According to a Eloxx Pharmaceuticals media release, Eloxx Pharmaceuticals acquired Sevion Therapeutics, and the company is called as Eloxx Pharmaceuticals.
    • 10 Sep 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 29 Aug 2014 Results published in the Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top